Ordering

How to Order

To order molecular testing and/or Point2™ fluid chemistry testing and specimen storage, download a requisition form

Turnaround Time

Expect a PancraGEN® report delivered within 10 to 14 business days from the date of the requisition form (and sample, if applicable) submission.

Easy to Use

*0.2mL is the lower limit of cyst fluid needed for testing. Providing additional cyst fluid volume, as possible, is encouraged. Specimens submitted that do not meet volume requirements will be tested using a dilution protocol or the ordering physician may be contacted for testing priority.

Point2™CEA was previously AccuCEA™.

Interpace Diagnostics Directory of Services

Download

International
Ordering

TAP Molecular Testing is the international distributor for all Interpace Diagnostics molecular tests.

Learn More

Point2™ Fluid Chemistry Testing

Our Point2™ assays for CEA, glucose, and amylase are highly accurate and specifically developed for pancreatic cyst fluid.9

Only 0.2mL of pancreatic cyst fluid
are required for each assay*9

All Point2™ tests are

  • Validated for use specifically with pancreatic cyst fluid9
  • Able to provide an accurate result—even with viscous or bloody samples9
  • Able to be reflexed to PancraGEN® for molecular testing

Results are typically reported within 1-3 business days.

Fluid chemistry results should be reviewed in relation to the patient’s medical history and current conditions.

* 0.2mL is the lower limit of cyst fluid needed for testing. Providing additional cyst fluid volume, as possible, is encouraged. Specimens submitted that do not meet volume requirements will be tested using a dilution protocol or the ordering physician may be contacted for testing priority.

Point2™CEA was previously AccuCEA™.

Limitations and Disclaimers1

Although PancraGEN is highly specific for malignancy, some malignant cysts may not be detected. There may also be individuals who are falsely identified as having a malignant cyst. Diagnosis and appropriate patient management are the responsibility of the referring physician or health care provider.

References

  1. Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2015;47(2):136-146.
  2. V. Chernyak et al, Incidental pancreatic cystic lesions Radiology 2015 274 161-9
  3. BU Wu, et al, Prediction of malignancy in cystic neoplasms of the pancreas: a population based cohort study, Am J Gastro 2014 109 121-9
  4. Loren D, Kowalski T, Siddiqui A, et al. Influence of integrated molecular pathology test results on real-world management decisions for patients with pancreatic cysts: analysis of data from a national registry cohort. Diagnostic Pathology. 2016;11:5. doi:10.1186/s13000-016-0462-x.
  5. Gaujoux S., , Brennan, M., et al. Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-year Time Period. J Am Coll Surg. 2011 April; 212(4): doi:10.1016/j.jamcollsurg.2011.01.016.
  6. Kaimalkliotis, P., Riff, B., et al. Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the Pancreas. Clinical Gastroenterology and Hepatology 2015;13:1808–1815: doi:10.1016/j.cgh.2015.03.017
  7. Kushnir VM, Mullady DK, Das K, et al. J Clin Gastroenterol. 2019;53(9):686-692. DOI: 10.1097/MCG.0000000000001118.
  8. Gonda TA, Viterbo D, Gausman V, et al. Clin Gastroenterol Hepatol. 2017;15:913-919.
  9. Data on File.